Science ❯ Medical Research ❯ Clinical Trials ❯ Phase 3 Studies
Expected to close in the third quarter of 2025, the deal secures Lilly’s control of VERVE-102, a Fast Track–designated gene-editing therapy in Phase 1b trials.
